Novartis CEO Warns of Sector Headwinds Amid U.S. Drug Pricing Shifts

Novartis CEO Vas Narasimhan has issued a stark warning regarding the trajectory of U.S. pharmaceutical pricing policies under the Trump administration, suggesting that the industry is approaching a critical inflection point. According to Narasimhan, the long-term implications of current policy directions are significant and will soon impact both drug manufacturers and the patients they serve. The executive specifically pointed to the 'Most Favored Nation' (MFN) pricing model, stating that the reality of this framework is expected to set in over the next 18 months. This policy shift creates a challenging environment for maintaining the pricing power necessary to sustain high-cost research and development. Beyond the United States, Narasimhan is urging governments in Japan and Europe to urgently reform how they reward pharmaceutical innovation. He warned that if these regions do not adapt their reimbursement and reward structures, the industry may face delays in introducing novel medicines to those markets, potentially restricting patient access to cutting-edge therapies. For the broader market, these comments signal a growing tension between government cost-containment efforts and the capital-intensive nature of drug development. Investors in the pharmaceutical sector may see increased volatility as companies navigate these regulatory pressures across multiple major jurisdictions.